Traditionally, advanced follicular lymphoma was treated with traditional chemotherapy regimens, either CHOP or CVP, which could induce remission but had little effect on overall survival. The discovery of the first monoclonal antibody, rituximab, altered treatment protocols fundamentally, causing much longer and more reliable responses to treatment. Relapsing follicular lymphoma may be treated with alternative drug regimens or an allogeneic or autologous stem-cell transplant. Several advanced new drugs show promise in treating the disease.
1. Watch & Wait (W&W)
2. First-Line Treatment for Follicular Lymphoma
3. Consolidation for Follicular Lymphoma
4. Maintenance for Follicular Lymphoma
5. Second-Line (and Subsequent) Treatment for Follicular Lymphoma
7. New Therapies
Novel Antibodies -- The TRAIL-R1 receptor is targeted by mapatumumab.
Protein Inhibitors and Enzyme Inhibitors -- New drugs that may inhibit the Bcl-2 protein include navitoclax.
See John Gribben, "How I Treat Indolent Lymphoma," Blood (2007).
For mantle cell lymphoma, see Michele Ghielmini and Emanuele Zucca, "How I Treat Mantle Cell Lymphoma," Blood (2009). For diffuse large B-cell lymphoma (DLBCL), see James Armitage, "How I Treat Patients with Diffuse Large B-Cell Lymphoma," Blood (2007); and Michael Pfreundschuh, "How I Treat Elderly Patients with Diffuse Large B-Cell Lymphoma," Blood (2010).